Zydus Cadila has received tentative approval from the USFDA to market Pimavanserin Tablets, 10 mg (US RLD: Nuplazid Tablets). Pimavanserin is used to treat the symptoms of a certain mental/mood disorder (psychosis) that might occur with Parkinson's disease. It helps
lessen symptoms such as seeing or hearing things that are not there (hallucinations) and false beliefs (delusions).
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 325 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
